RxDoctor Payments Data

Yanina Kovler, MD

Internal Medicine · Brooklyn, NYNPI 1124212998

Payments from drug & device makers

$27,470in general payments, 2019–2025

Across 510 payments — averaging $53.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$13K
  • Ironwood Pharmaceuticals, Inc$5K
  • Amgen$3K
  • GSK$822
  • AstraZeneca$707
  • Nestle Healthcare Nutrition Inc.$572
  • plus $4K from 28 others

What the payments were for

  • Speaking & faculty fees$15,72557%
  • Food & beverage$11,70343%
  • Education$420%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,470 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$444,750
Medicare patients
87
Services billed
8,233

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZenpepLipase/Protease/Amylase217$474,509
Trelegy ElliptaFluticasone/Umeclidin/Vilanter118$77,166
LinzessLinaclotide134$75,546
Repatha SureclickEvolocumab132$71,039
TrulicityDulaglutide51$57,384
OtezlaApremilast11$53,280
OpzeluraRuxolitinib Phosphate22$45,342
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate41$42,757
IbsrelaTenapanor Hcl26$41,203
Diclofenac Sodium105$40,214
MyrbetriqMirabegron77$37,670
CreonLipase/Protease/Amylase34$32,831
JanumetSitagliptin Phos/Metformin Hcl48$28,938
NamzaricMemantine Hcl/Donepezil Hcl43$24,944
JanuviaSitagliptin Phosphate39$22,207

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aimmune Therapeutics, Inc.Zenpep$400$474,509217 claims
AbbVieLinzess, Creon, Namzaric, Ubrelvy, Restasis$13,252$158,358310 claims
Lilly USA, LLCTrulicity, Mounjaro$464$79,14273 claims
GSKTrelegy Ellipta$822$77,166118 claims
AmgenOtezla, Prolia$2,548$71,03222 claims
MerckJanumet, Januvia$14$51,14587 claims
Incyte CorporationOpzelura$41$45,34222 claims
Ardelyx, Inc.Ibsrela$469$41,20326 claims
Astellas Pharma US IncMyrbetriq$316$37,67077 claims
AstraZenecaBreztri Aerosphere$707$17,63129 claims
NovartisEntresto$334$8,12112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →